Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
K-Ras-PDEδ-IN-1 is a novel and potent competitive K-Ras-PDEδ inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar Kd of 8 nM.
ln Vitro |
The PaTu8902/Panc1 CTG test yields an IC50 value of 12.3 μM for K-Ras-PDEδ-IN-1 [1].
|
---|---|
ln Vivo |
K-Ras-PDEδ-IN-1 (10 mg/kg; single dosage) was injected orally or intraperitoneally (IP) in four different vehicles: A = 5% Tween-80, 50% NaCl, 45% H2O; B = 20% DMSO, 80% PEG200; C = 15% DMSO, 9.5% Cremophor EL/EtOH (1:1), 75.5% H2O. The chemical was identified in plasma at extremely low levels only after oral administration; however, after intraperitoneal delivery of 10 mg/kg in vehicles A, B, or C, there were notable increases in plasma concentrations [1]. The K-Ras-PDEδ-IN-1 (iv; 3 mg kg; single dose; 24 hours) demonstrated a significantly higher terminal half-life (t1/2=0.4 hours) in comparison to the compound 93 values for t1/2, CO, AUC0-tz, AUC0.inf-obs, Clob, and Vss0-inf-obs, which are 4.1 hours, 2790.9 ng/ml, 1646.4 h.ng/ml, 1662.5 h.ng/ml, 1.8 liters/hour/kg, and 5.9 liters/kg[1].
|
References |
[1]. Sandip Murarka, et al. Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site. Chemistry. 2017 May 2;23(25):6083-6093.
|
Molecular Formula |
C25H26FN5O2
|
---|---|
Molecular Weight |
481.669
|
Exact Mass |
481.1745
|
Elemental Analysis |
C, 67.33; H, 6.49; N, 2.91; O, 9.96; S, 13.31
|
CAS # |
1841464-21-8
|
SMILES |
O=C(NCCC1=CC=C(F)C=C1)CCCN2N=C(C)C3=CN(C4=CC=C(C)C=C4)N=C3C2=O
|
InChi Key |
RRELLHHWESTKAK-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C25H26FN5O2/c1-17-5-11-21(12-6-17)31-16-22-18(2)28-30(25(33)24(22)29-31)15-3-4-23(32)27-14-13-19-7-9-20(26)10-8-19/h5-12,16H,3-4,13-15H2,1-2H3,(H,27,32)
|
Chemical Name |
N-(4-fluorophenethyl)-4-(4-methyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)butanamide
|
Synonyms |
KY-226; KY 226; KY226;
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~27.93 mM)
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0761 mL | 10.3806 mL | 20.7611 mL | |
5 mM | 0.4152 mL | 2.0761 mL | 4.1522 mL | |
10 mM | 0.2076 mL | 1.0381 mL | 2.0761 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.